Israel covid-19 outbreak reports Israel

News Scan for Jun 03, 2022

Reading now: 755
www.cidrap.umn.edu

Data show Paxlovid halves the risk of severe Omicron disease, deathA study of 4,737 COVID-19 patients in Israel conducted during the Omicron surge concludes that Pfizer's antiviral drug Paxlovid roughly halves the risk of severe COVID-19 or death, according to findings published yesterday in Clinical Infectious Diseases.For the retrospective cohort study, researchers analyzed data on 180,351 COVID-19 adult patients from the Clalit Health Services database and the Israeli Ministry of Health COVID-19 database who tested positive in January or February.

Of those, 4,737 received Paxlovid, an oral pill.They found that both Paxlovid and complete vaccination were tied to statistically significant decreases in the rate of severe COVID-19 or death, with Paxlovid lowering the risk 46% (hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.39 to 0.75) and vaccination lowering the risk 80% (HR, 0.20; 95% CI, 0.17 to 0.22)."Paxlovid appears to be more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease (interaction p-value <0.05 for all)," the study authors write. "No significant interaction was detected between Paxlovid treatment and COVID-19 vaccination status."The researchers note that having a lower socioeconomic status, belonging to an Arab population, and having received COVID vaccine were all tied to less chance of being prescribed Paxlovid.They conclude, "In this real-world study, we show that treatment with Paxlovid in the first 5 days of SARS-CoV-2 infection is associated with markedly reduced risk of progression to severe COVID-19 or mortality, regardless of vaccination status for SARS-CoV-2."Jun 2 Clin Infect Dis studyStudy details emergence of

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA